Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: ten years of successful antivascular therapy.
Eggermont
Alexander M M
AM
Department of Surgical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, 301 Groene Hilledijk, 3075 EA Rotterdam, Netherlands. eggermont@chih.azr.nl
ten Hagen
Timo L M
TL
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D010478:Chemotherapy, Cancer, Regional Perfusion; D002986:Clinical Trials as Topic; D005121:Extremities; D006801:Humans; D023821:Limb Salvage / Q000379:methods; D008545:Melanoma / Q000628:therapy*; D008558:Melphalan / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D009389:Neovascularization, Pathologic / Q000628:therapy; D012509:Sarcoma / Q000628:therapy*; D012878:Skin Neoplasms / Q000628:therapy*; D012983:Soft Tissue Neoplasms / Q000628:therapy*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use*
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D014409:Tumor Necrosis Factor-alpha; D008558:Melphalan